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Abbreviations
AUC  Area under curve
CEF  Chick embryo fibroblast
GUT  Genitourinary tract
IU  Infectious unit
MVA  Modified vaccinia Ankara
PAP  Prostatic acid phosphatase
PCa  Prostate cancer
PD-1  Programmed cell death-1
PD-L1  Programmed cell death ligand-1
PFA  Paraformaldehyde
PSA  Prostate-specific antigen
SFC  Spot-forming cell
STEAP1  Six transmembrane epithelial antigen of the 
prostate 1
TRAMP  Transgenic adenocarcinoma of the mouse 
prostate
VEE VRP  Venezuelan equine encephalitis virus replicon 
particle
Introduction
Prostate cancer (PCa) is the most common non-skin can-
cer in males and the second leading cause of cancer deaths, 
with an estimated 233,000 men diagnosed in 2014 and 
29,480 deaths predicted in the USA [1]. Although there 
have been impressive advances made in recent years in the 
treatment of PCa, available therapies for advanced stages 
of the disease are still limited and their effectiveness is far 
from satisfactory. Therefore, the development of alternative 
therapies, aiming at activating host anti-tumour immunity 
Abstract Prostate cancer possesses several characteris-
tics that make it a suitable candidate for immunotherapy; 
however, prostate cancer vaccines to date demonstrate 
modest efficacy and low immunogenicity. The goal of the 
present pre-clinical study was to explore the immunogenic 
properties and protective efficacy of a novel prostate can-
cer immunotherapy based on the heterologous prime–boost 
viral-vectored vaccination platform. The simian adenovi-
rus, ChAdOx1, and modified vaccinia Ankara virus, MVA, 
encoding a prostate cancer-associated antigen, the six trans-
membrane epithelial antigen of the prostate 1 (STEAP1), 
induced strong sustained antigen-specific CD8+ T-cell 
responses in C57BL/6 and BALB/c male mice. Unex-
pectedly, the high vaccine immunogenicity translated into 
relatively low protective efficacy in the murine transplant-
able and spontaneous models of prostate cancer. A com-
bination of the vaccine with PD-1 blocking antibody sig-
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using appropriate immunological targets, remains a 
priority.
Although promising, the use of therapeutic vaccina-
tion in cancer presents many challenges, with tolerance 
to self-antigens and active immunosuppressive mecha-
nisms mounted by tumours being two major factors ham-
pering cancer vaccine efficacy. The two most advanced 
PCa immunotherapies, the licensed product Sipuleucel-
T [2] and ProstVac [3] currently being tested in Phase III 
trial, target two well-defined PCa antigens, prostatic acid 
phosphatase (PAP) and prostate-specific antigen (PSA), 
respectively.
In this study, we have evaluated an alternative PCa-asso-
ciated antigen, the six transmembrane epithelial antigen 
of the prostate 1 (STEAP1), as a vaccine target in mouse 
models. STEAP1 is expressed only in the prostate among 
normal tissues and overexpressed in various cancer types 
including prostate, bladder, lung, ovarian cancer and Ewing 
sarcoma [4]. Its unique and restricted expression pattern 
and growing evidence of its role in PCa initiation and pro-
gression [5–7] make STEAP1 an excellent target for a PCa 
vaccine.
However, STEAP1 was shown to be poorly immuno-
genic when delivered as a DNA vaccine followed by Ven-
ezuelan equine encephalitis virus replicon particle (VEE 
VRP) boost [8]. In this study, we have deployed a highly 
immunogenic vaccination platform based on the two 
recombinant viral vectors, the simian adenovirus ChAdOx1 
[9] and modified vaccinia virus Ankara (MVA), for the 
delivery of STEAP1 antigen and induction of STEAP1-
specific cellular immune responses. This heterologous 
prime–boost regime has induced exceptionally strong 
T-cell responses in pre-clinical infectious disease models 
[10–12]. Also, ChAd–MVA vectors have been a very effec-
tive means of inducing CD8+ T-cells in humans—across 
32 trials now in malaria, Flu, TB, HCV, HIV and Ebola 
using different inserts, and they have been safe in over 
1200 vaccines, including adults, children and infants [13–
17]. However, this approach has never been tested before in 
cancer settings.
In this study, for the first time a therapeutic vaccination 
strategy based on ChAdOx1–MVA prime–boost has been 
evaluated as a means of breaking tolerance and mediating 
tumour-protective efficacy in mouse transplantable and 
autochthonous models of PCa.
Materials and methods
Mice and cell lines
Six-week-old male C57BL/6 and BALB/c mice were pur-
chased from Harlan, UK. TRAMP breeder female mice 
were purchased from Jackson Laboratories, and the colony 
was maintained in pure C57BL/6 background.
Mouse care and experimental procedures were carried 
out in accordance with the terms of the UK Animals (Sci-
entific Procedures) Act Project License (PPL 30/2947) and 
approved by the University of Oxford Animal Care and 
Ethical Review Committee.
TRAMP-C1 cell line and HB-51 hybridoma (clone 
28-8-6S) secreting mAb against MHC class I were pur-
chased from the ATCC and maintained according to ATCC 
recommendations.
ChAdOx1 and MVA viral vector construction
A DNA sequence encoding mouse STEAP1 antigen was 
obtained from Source BioScience, UK. The construction 
of ChAdOx1 vector was described previously [9]. The 
full-length mouse STEAP cDNA under a CMV immedi-
ate early promoter was sub-cloned from a pENTR plasmid 
into the E1 locus of the pBAC ChAdOx1-DEST genomic 
clone by Gateway™ cloning. The construct was then used 
to transfect HEK293A cells to generate the recombinant 
adenovirus expressing the antigen. The MVA-GFP shut-
tle vector drives the expression of STEAP1 under the P7.5 
early/late promoter inserted at the thymidine kinase locus 
of MVA and the GFP from the fowlpox FP4b late promoter. 
The plasmid was transfected into MVA-infected primary 
chick embryo fibroblasts (CEFs), and recombinant virus 
was isolated by selection of GFP-positive plaques, ampli-
fied, purified over sucrose cushions and titrated in CEFs 
according to standard practice. The integrity, identity and 
purity of the viruses were confirmed by PCR analysis.
In vivo studies
Immunogenicity of STEAP1 antigen expressed from 
the viral vectors was assessed in C57BL/6, BALB/c and 
TRAMP male mice. A dose of 107 or 108 infectious units 
(IU) of ChAdOx1 virus and 106 or 107 plaque-forming 
units (PFU) of MVA was given intramuscularly (i.m.) in a 
total volume of 50 µl per animal. The alternating immuni-
sations with ChAdOx1.STEAP1 and MVA.STEAP1 vac-
cines were performed 1–3 weeks apart with a total number 
of 2–6 vaccinations. Transgene-specific immune responses 
in every animal were evaluated in blood 10–14 days after 
the prime and 7–10 days after the boost and in spleen at 
the point of sacrifice. Anti-mouse monoclonal antibodies 
against PD-1, PD-L1 and rat IgG2a were purchased from 
BioXCell and administered intraperitoneally at the dose of 
300 µg per mouse weekly.
To assess vaccine tumour-protective efficacy in a trans-
plantable tumour model, wild-type C57BL/6 male mice 
were inoculated with 2 × 106 TRAMP-C1 cells in 100 µl 
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PBS subcutaneously (s.c.) into the right flank. Upon estab-
lishment of palpable tumours, an immunisation course as 
described above was initiated. Tumour growth was moni-
tored 3 times weekly, and animals were killed when tumour 
size reached 10 mm in any direction. Tumour volume was 
calculated as length (mm) × width2 (mm) × 0.5.
To assess vaccine tumour-protective efficacy in an 
autochthonous tumour model, an immunisation course 
of TRAMP male mice was initiated at 6–7 weeks of 
age. When mice reached 24–27 weeks of age, they were 
euthanised and the entire genitourinary tract (GUT) was 
dissected, weighed, paraformaldehyde (PFA)-fixed and 
paraffin-embedded.
Measurement of STEAP1‑specific immune responses 
by IFN‑γ ELISPOT
An ex vivo IFN-γ ELISPOT assay was performed using 
Multiscreen-IP ELISPOT plates (Millipore) and mIFN-γ 
ELISPOT kit (ALP) (Mabtech). A mouse STEAP1 pep-
tide library synthesised by Mimotopes (UK) consisting of 
15-mer peptides overlapping by 10 amino acids and span-
ning the whole length of the STEAP1 protein was used for 
cell stimulation. Mouse PBMCs or splenocytes were incu-
bated in triplicate wells with STEAP1 pools or individual 
peptides for 18–22 h or left unstimulated prior to detection 
of spot-forming cells (SFCs). ELISPOT plates were ana-
lysed using an AID ELISPOT counter (AID Diagnostika 
GmbH).
Measurement of STEAP1‑specific immune responses 
and MHC class I expression by flow cytometry
Mouse PBMCs or splenocytes were stimulated ex vivo with 
STEAP1 peptide pools in the presence of Golgi-Plug (BD) 
for 6 hours (h), labelled with CD4-FITC, CD8-APC, fixed-
permeabilised in CytofixCytoperm buffer (BD) and stained 
with IFN-γ-PE antibody.
TRAMP-C1 and IFN-γ-treated TRAMP-C1 cells 
(100 U/ml for 48 h) were dissociated and incubated with 
HB-51 hybridoma supernatant or control medium followed 
by anti-mouse IgG-FITC secondary antibody. All antibod-
ies used in this study were obtained from eBioscience. 
Flow cytometry was performed on a BD LSRII™ analyser 
and data analysed with FlowJo software.
Analysis of STEAP1 expression on transcriptional 
and translational level
STEAP1 mRNA expression in TRAMP-C1 cells and thymi 
of C57BL/6 mice was detected by semi-quantitative reverse 
transcription PCR. Total RNA was extracted with RNeasy 
Plus minikit (Qiagen), and a total of 2 μg of RNA was used 
to synthesise the first single-strand cDNA using QuantiTect 
Reverse Transcription kit (Qiagen) according to the manu-
facturers’ guidelines. For RT-PCR amplification, the fol-
lowing priming pairs have been used: 5′-GGCATCCTCA 
CCCTGAAGTA and 5′-AGCACTGTGTTGGCGTACAG 
for mouse β-actin, 5′-AGCACTGTGTTGGCGTACAG and 
5′-TACAACCTGGAGGCCATCTC for mouse STEAP1, 
5′-AGCACTGTGTTGGCGTACAG and 5′-AGCACT-
GTGTTGGCGTACAG for mouse 5T4. Transcripts were 
amplified using 98 °C denaturation, 60 °C annealing, and 
72 °C extension for a total of 35 cycles.
STEAP protein expression in TRAMP-C1, LNCaP, 
PC3 and HEK293A cells infected with ChAdOx1 vec-
tors (MOI = 10, 24 h) was detected by Western blotting. 
Cell lysates were obtained using RIPA buffer (Pierce Bio-
technology) supplemented with protease inhibitor cocktail 
(Roche Diagnostics), and total protein concentration was 
determined by BCA protein assay (Thermo Fisher Scien-
tific). For each cell line, 10 μg of total protein was sub-
jected to SDS-PAGE and immunoblot analysis using rabbit 
anti-STEAP polyclonal antibody (Santa Cruz Biotechnol-
ogy), followed by AP-conjugated secondary antibody 
(Jackson ImmunoResearch) and E SIGMAFAST BCIP/
NBT detection system (Sigma).
Immunohistochemistry (IHC) of TRAMP biopsies
Five-µm sections of PFA-fixed paraffin-embedded TRAMP 
GUTs were used in standard H&E staining or in IHC with 
anti-Ki-67 antibody (Cell Signalling) or anti-CD3 antibody 
(Abcam) and biotinylated secondary antibodies (Vector 
Lab). Immunoreactivity was visualised via avidin–biotin 
reagent and DAB substrate according to manufacturer’s 
instructions followed by counterstaining with Meyer’s 
haematoxylin.
Light microscopy pictures were obtained using a Leica 
DM5500B microscope and analysed with ImageJ software. 
Positivity for Ki-67 and CD3 markers was evaluated by cal-
culating the ratio between brown-stained and blue-stained 
areas.
Statistical analysis
Descriptive data were analysed with Prism 6.0 statisti-
cal software (GraphPad Software). All P values < 0.05 
were considered statistically significant. Group compari-
sons were made by one-way ANOVA test or two-tailed 
Student’s t test. Survival curves were created with the 
Kaplan–Meier method, and the log-rank test was used to 
determine differences in survival between groups of mice. 
Each experiment presented in this manuscript is represent-
ative of at least 2 experiments using a minimum of 5 ani-
mals per group.
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Results
ChAdOx1–MVA vaccination regime elicits strong 
STEAP1‑specific CD8+ T‑cells responses
In the first round of experiments, we set out to investigate 
whether immunological tolerance to STEAP1 can be bro-
ken by the ChAdOx1–MVA-based vaccine regime and 
to assess the magnitude of induced responses. C57BL/6, 
BALB/c and transgenic TRAMP male mice were primed 
with ChAdOx1.STEAP1 vaccine followed by MVA.
STEAP1 boost 3 weeks later. An ex vivo IFN-γ ELISPOT 
assay using a pool of STEAP1 peptides covering the entire 
protein was performed on PBMCs after each vaccination. 
As shown in Fig. 1a, STEAP1-specific T-cell responses 
could be detected after a single priming immunisation in 
both mouse strains, and frequencies of antigen-specific 
T-cells significantly increased after MVA boost.
To assess the relative contribution of CD4+ and CD8+ 
T-cells in IFN-γ secretion, antigen-specific responses were 
analysed by flow cytometry. Representative results from 
one mouse post-MVA boost shown in Fig. 1b-c indicate 
that IFN-γ is predominantly secreted by CD8+ T-cells with 
approximately 1 % of lymphocytes in circulation being 
STEAP1-specific after boost vaccination.
In order to assess the breadth of the induced responses, 
splenocytes from vaccinated mice were exposed to the pool 
of STEAP1 peptides covering the entire protein as above, 
and to this pool dissected into 7 individual pools, each con-
taining ten adjacent 15-mer peptides overlapping by 10 
amino acids. As shown in Fig. 1d, only pools 4 and 7 were 
able to stimulate IFN-γ secretion. Putative CD8+ T-cell 
epitopes that could potentially bind to MHCI have been 
predicted by BIMAS software and validated previously 
[8]. A sequence alignment of the predicted MHCI epitopes 
with the 15-mer peptides constituting pools 4 and 7 dem-
onstrated that these pools contain the predicted epitopes 
STEAP186–193 and STEAP326–335, respectively. Further 
dissection of pool 4 confirmed that vaccination-induced 
STEAP1-specific CD8+ T-cell responses were directed 
against the previously identified epitope STEAP186–193 
RSYRYKLL (Fig. 1e).
Intrigued by the strength of the immune response elicited 
against a self-antigen, that was comparable with responses 
induced to pathogens by the same vaccination regime [13, 
16], we have interrogated a murine thymus for STEAP1 
expression. As shown in Fig. 1f, the STEAP1 mRNA tran-
script was not amplified from total thymic RNA, while a 
shared tumour antigen, 5T4, and β-actin were both ampli-
fied by RT-PCR. This finding suggests that precursors with 
STEAP1-specific TCR repertoire could have escaped nega-
tive thymic selection due to minimal thymic expression of 
STEAP1. Of note, a high intensity band corresponding to 
the STEAP1 mRNA transcript was detected by RT-PCR of 
total TRAMP-C1 cell RNA.
ChAdOx1–MVA vaccination regime is protective in a 
transplantable tumour model
To determine whether strong STEAP1-specific T-cell 
responses could protect against tumour growth, mice were 
challenged s.c. with TRAMP-C1 cells. Upon establishment 
of palpable tumours, mice were primed with ChAdOx1 
vectors expressing STEAP1 or control antigen GFP, and 
3 weeks later boosted with the respective MVA vectors 
(Fig. 2a). The tumour volume was monitored at regular 
intervals throughout the experiment. As demonstrated in 
Fig. 2a, tumour growth was significantly delayed in treated 
mice compared to controls initially (weeks 4–5); however, 
over time the immune system started losing its ability to 
control tumour outgrowth (week 6). To quantitate and com-
pare tumour growth kinetics, tumour growth curves of each 
mouse in control and treated groups were plotted (Fig. 2b). 
Single numerical values for individual curves were 
obtained for an area under the curve (AUC) analysis [18], 
which demonstrated a trend towards efficacy of STEAP1-
targeting vaccine in delaying tumour progression (Fig. 2c).
Optimisation of vaccination regime and PD‑1 blockade 
improve protective efficacy of STEAP1 vaccine in a 
transplantable model
Our tumour challenge studies demonstrated that vaccine-
induced immune responses can be tumour-protective at 
the onset of tumour development, but at a later stage the 
immune system fails to keep aggressive and fast-growing 
TRAMP-C1 tumours under control. We speculated that 
more frequent boosts with lower dose of vaccine may main-
tain better control of tumour growth. First, we tested the 
effect of vaccine dose reduction on the number of STEAP1-
specific cells after prime with ChAdOx1.STEAP1. As 
shown in Fig. 3a, a tenfold reduction in the original dose 
resulted in similar frequency of antigen-specific T cells. 
Next, we compared the immunogenicity of three vaccina-
tion regimes: the original high dose of ChAdOx1 and MVA 
vectors given at 3-week intervals, the tenfold reduced dose 
of these vectors given at 3-week intervals and the reduced 
dose of these vectors given at 1-week interval (Fig. 3c). 
Interestingly, although the frequencies of T-cells after 
prime were comparable between 108 and 107 IU doses, 4 
weekly boosts with reduced vaccine dose resulted in much 
stronger T-cell responses compared to the responses after 2 
immunisations of high-dose vaccines given at 3-week inter-
vals (Fig. 3b). The vaccination regime with reduced dose 
vectors administered at weekly intervals also translated into 
superior protection against tumour challenge compared 
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to both standard and reduced doses given at 3-week inter-
vals as demonstrated by the survival curves (Fig. 3d) and 
tumour growth kinetics (Fig. 3e).
In an attempt to further increase vaccine efficacy, we 
also tested it in combination with PD-1/PD-L1 blocking 
antibodies. Checkpoint inhibitors have been remarkably 
successful in clinical trials in several cancer types, although 
so far there has been little evidence of efficacy in PCa 
patients, either as a monotherapy or in combination with a 
vaccine. A combinatorial approach has yet not been tested 
in a mouse PCa model, so we set out to fill in this gap. 
C57BL/6 mice were inoculated with TRAMP-C1 cells, 
and 1 week later a treatment course of the STEAP1 vac-
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Fig. 1  ChAdOx1–MVA prime–boost regimen induces strong STEAP1-
specific CD8+ T-cell responses. Mice were immunised i.m. with 108 IU 
of ChAdOx1.STEAP1 vector followed by 107 PFU of MVA.STEAP1 
3 weeks later. Representative data of 3 biological replicate experiments 
are shown. a Graphs show data of ex vivo blood ELISPOT performed 
after priming and boosting immunisations in C57BL/6 (closed squares), 
TRAMP (open squares) and BALB/c (closed triangles) male mice. 
Bars represent median responses as spot-forming cells (SFC) per 106 
PBMCs. P values are indicated. b, c Surface staining for CD4 and CD8 
markers and IFN-γ intracellular cytokine staining (ICS) of PBMCs was 
performed in control and STEAP1-vaccinated TRAMP mice after MVA 
boost. b Graphs show the percentage of IFN-γ-positive CD8+ T-cells 
(left panels) and CD4+ T-cells (right panels) in one of the control and 
treated mice. c Relative proportion of STEAP1-specific CD8+ T-cell 
responses in peripheral blood of control and STEAP1-vaccinated mice 
after boost. Each symbol shows frequency of STEAP1-specific IFN-γ-
secreting CD8+ T-cells in individual animals. Δ values in percentage 
are calculated subtracting values obtained in unstimulated cells in the 
two groups of mice. Bars represent median. P value is indicated. d, e 
Epitope mapping of STEAP1-specific responses. To dissect vaccination-
induced T-cell responses, splenocytes isolated from ChAdOx1–MVA 
STEAP1-vaccinated mice were either stimulated with the total pool of 
STEAP1 peptides, all peptides separated into 7 pools (d), or individual 
overlapping peptides of pool 4 (e). The IFN-γ secretion was measured 
by ELISPOT assay. Bars represent SEM (d) and median (e). f Compara-
tive expression of STEAP1 mRNA transcripts in TRAMP-C1 cells and 
murine thymus. TRAMP-C1 cell and thymic cDNA were amplified with 
primers specific for β-actin (lane 1), STEAP1 (lane 2) and 5T4 (lane 3)
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initiated. As a result, 80 % of mice receiving combination 
therapy with anti-PD-1 remained tumour-free, whereas all 
the other groups succumbed to tumours suggesting a syn-
ergistic effect of the vaccine and PD-1 blockade, resulting 
in tumour growth delay and significantly improved survival 
(Fig. 4a) as compared to STEAP1 vaccination combined 
with isotype control antibody or anti-PD-L1 mAbs. Impor-
tantly, anti-PD-1 treatment alone did not improve survival 
of tumour-challenged mice (Fig. 4b). Tumour growth kinet-
ics of individual mice, mean tumour volumes per group and 
AUC analysis are shown in Fig. 4d. Of note, checkpoint 
blockade did not have any effect on the level of T-cells in 
the circulation as measured by ex vivo IFN-γ ELISPOT 
(Fig. 4c).
ChAdOx1–MVA vaccination regime is modestly 
protective in an autochthonous model of PCa
Next, we assessed the vaccine efficacy in the more 
physiologically relevant TRAMP mouse PCa model. 
TRAMP male mice uniformly develop prostate tumours 
due to expression of SV40Tag under the control of a 
prostate-specific androgen-regulated promoter [19]. By 
22–25 weeks of age, the tumour progresses to advanced 
prostatic adenocarcinoma and mice die of metastatic dis-
ease 10–20 weeks later. Among vaccine efficacy readouts 
in the TRAMP model, the ratio of GUT to the whole body 
weight can be considered as a surrogate marker for tumour 
burden. To assess ChAdOx1–MVA vaccine, TRAMP male 
mice were immunised with STEAP1 vaccine at 3-week 
intervals starting at 6–8 weeks of age or left untreated until 
the age of 24–26 weeks. Mice were then sacrificed and 
GUTs were dissected and weighed. The whole body weight 
at the point of sacrifice was comparable in both groups 
(data not shown); however, GUT to body weight ratio in 
STEAP1-vaccinated mice was lower than in control ani-
mals (Fig. 5a). The trend towards less advanced cancer was 
also confirmed by histopathological analysis of prostate tis-
sue sections (data not shown) and immunohistochemistry 
(Fig. 5b). As shown in Fig. 5b, the quantification of Ki-67 
positive staining shows higher values in the control group 
as compared to STEAP1-vaccinated mice, which in turn 
demonstrated a slight increase in CD3+ tumour-infiltrating 
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Fig. 2  ChAdOx1–MVA prime–boost regimen reduces tumour 
growth rate in a transplantable tumour model. C57BL/6 mice were 
challenged subcutaneously with TRAMP-C1 cells and subsequently 
immunised i.m. at 3-week intervals with 108 IU of ChAdOx1.
STEAP1 and 107 PFU of MVA.STEAP1, or equivalent doses of GFP-
expressing vectors (control). Tumour size was measured 3 times per 
week, and volumes were calculated as described in “Materials and 
methods”. Representative data of 3 biological replicate experiments 
are shown. a Graphs show tumour volumes of individual mice in 
control and STEAP1-vaccinated groups expressed in mm3 calculated 
at weeks 2, 4, 5 and 6 post-TRAMP-C1 cell challenge. Bars repre-
sent median. b Tumour growth curves for each individual mouse in 
control (left panel) and STEAP1-vaccinated (middle panel) groups, 
and mean tumour volumes ± SEM comparison between the two 
groups (right panel) c Assessment of vaccine efficacy by end-point 
area under the curve (AUC) analysis (control group—closed circles; 
STEAP1 group—closed squares). P values are shown. Bars represent 
median
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Inefficient antigen presentation by tumour cells, 
low‑avidity T‑cells and tumour adaptive immune 
resistance are underlying causes of modest vaccine 
efficacy
Modest tumour-protective efficacy of the vaccine despite 
strong STEAP1-specific CD8+ T-cell responses has led us 
to investigate potential underlying mechanisms of this phe-
nomenon. Firstly, the TRAMP-C1 cell line has been pre-
viously reported to express low levels of MHCI molecules 
[20] that could hamper presentation of STEAP1 epitopes 
on tumour cells. We confirmed this finding by incubating 
TRAMP-C1 cells with IFN-γ and staining them with anti-
mouse MHCI mAb. Only 16.7 % of TRAMP-C1 cells natu-
rally expressed MHCI molecules, while pre-treatment with 
IFN-γ raised MHCI expression to 87.6 % (Fig. 6a).
Although we have shown STEAP1 expression in 
TRAMP-C1 cells at a transcriptional level (Fig. 1d), we 
set out to investigate the expression of this antigen at the 
protein level. As shown in Fig. 6b, the band corresponding 
to STEAP1 protein is faint in TRAMP-C1 cells compared 
to LNCaP cells and ChAdOx1.STEAP-infected HEK293A 
cells used as positive control.
Poor presentation of STEAP1 antigen on the surface 
of TRAMP-C1 cells has also been confirmed in a func-
tional assay. TRAMP-C1 cells used as APCs in an ex vivo 
ELISPOT assay have not induced IFN-γ secretion by sple-
nocytes isolated from STEAP1-vaccinated mice. On the 
contrary, the same splenocytes could recognise TRAMP-
C1 cells pulsed with STEAP1 peptides (Fig. 6c). In paral-
lel, we tested the avidity of vaccination-induced effector 
cells by exposing them to serially diluted STEAP1 peptide 
pool. As shown in Fig. 6c, splenocytes require high concen-
trations of STEAP1 peptides to trigger IFN-γ secretion.
To conclude, in addition to low levels of MHCI–peptide 
complexes on the tumour cell surface, vaccination-induced 
T-cells are of low avidity, with both factors likely contribut-
ing to poor tumour control.
Discussion
Various antigen delivery systems of poorly immunogenic 
prostate tissue-specific antigens, including the heterologous 
viral vector prime–boost approach, have been utilised in 
the past and elicited only modest immune responses [2, 3, 
21, 22].
In the present study, we elected to evaluate a simian 
adenovirus prime–MVA boost vaccination platform, previ-
ously proved to be highly immunogenic in infectious dis-
ease settings, for its potential to break tolerance to self-anti-
gens. This vaccination approach had been shown to induce 










































































































STEAP1 reduced dose weekly
0 10 20 30 40 50
Days post tumour challenge
0 10 20 30 40 50













STEAP1 STEAP1 reduced dose
STEAP1 
reduced dose weekly
Fig. 3  Optimisation of ChAdOx1–MVA vaccination regime. 
C57BL/6 mice were inoculated subcutaneously with TRAMP-C1 
cells and randomised into three groups. Mice in group one were 
immunised i.m. with 108 IU of ChAdOx1.STEAP1 and 107 PFU of 
MVA.STEAP1 at 3-week intervals. Mice in group two received ten-
fold reduced doses of vectors, 107 IU of ChAdOx1.STEAP1 and 
106 PFU of MVA.STEAP1 at 3-week intervals. Mice in group three 
were immunised with tenfold reduced doses at 1-week interval. Rep-
resentative data of two biological replicate experiments are shown. 
ChAdOx1.STEAP1 is indicated as C, and MVA.STEAP1 is indicated 
as M. Blood samples were collected from mice in groups one and 
two 10 days post-prime a and in groups one and three 5 weeks post-
prime–boost b for ex vivo blood ELISPOT to compare magnitude of 
STEAP1-specific responses. P value is shown. Bars represent median 
spot-forming cells (SFC) per 106 PBMCs. c Schematic representa-
tion of immunisation protocol. d Kaplan–Meier survival curves of the 
three groups of vaccinated mice. Log-rank (Mantel–Cox) test P val-
ues are shown. e Tumour growth curves for each individual mouse in 
the three groups, mean tumour volumes ± SEM comparison between 
the three groups, and assessment of vaccine efficacy by area under the 
curve (AUC) analysis at day 35 post-TRAMP-C1 cell challenge. Bars 
represent median
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unprecedentedly high CD8+ T-cell responses against path-
ogens [23–25] and also CD4+ T-cell responses. We have 
demonstrated for the first time the ability of the ChAdOx1–
MVA vaccination strategy to induce strong sustained 
CD8+ T-cell responses to the tumour-specific self-antigen 
STEAP1 in murine models. In particular, ex vivo IFN-γ-
secreting antigen-specific CD8+ T-cells could be detected 
after a single priming immunisation, with frequencies fur-
ther increased by the MVA boost, with values comparable 
to the ones achieved by vaccinations against non-self-anti-
gens, therefore confirming that the ChAdOx1–MVA vac-
cination strategy is an efficient means of inducing CD8+ 
T-cell responses against weakly immunogenic TAAs. For 
comparison, the highest frequency of STEAP1-specific 
T-cells following a heterologous vaccination regime based 
on DNA prime–VEE VRP boost was 60 SFC per million 
PBMCs [8]. Of note, STEAP1-specific CD4+ T-cells have 
been detected after ChAdOx1–MVA vaccination, but they 
were predominantly IL-2 secreting.
Surprisingly, there is general lack of studies investigat-
ing immunotherapies targeting STEAP1 antigen in PCa set-
tings despite the fact that STEAP1 represents a promising 
antigenic target in this indication [5–7]. STEAP-specific 
immune reactivity has been demonstrated by two other het-
erologous vaccination strategies, DNA prime–MVA boost 
[26] and adenovirus prime–TRAMP cell lysate boost [27]; 
however, a direct comparison of the immunogenic potency 
of these two regimes with ChAdOx1–MVA is not possible 
as different assays were used to assess immunogenicity.
We have attempted to map CD8+ T-cell epitopes within 
the STEAP1 antigen. Notably, despite a large number of 
potential epitopes within STEAP1 predicted by MHCI 
binding software, the STEAP1-specific T-cell repertoire 
was narrow, with specificities directed only against two of 
the predicted epitopes. One of them, the H-2 Kb-restricted 
epitope RSYRYKLL (STEAP186–193), has also been identi-
fied by others [27].
Intrigued by unexpectedly strong immune responses 
induced against a self-antigen, we speculated that STEAP1 
immunogenicity could stem from a breach in the central 
tolerance mechanism and escape from thymic selection, 
a phenomenon that has been observed for TRP-2 antigen 
[28]. To this end, we tested STEAP1 expression in murine 
thymus and found that STEAP1 expression is not detect-
able at mRNA levels. The same result has been reported by 
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Fig. 4  Anti PD-1 antibodies improve efficacy of STEAP1 heterolo-
gous vaccination in the transplantable tumour model. C57BL/6 male 
mice were inoculated s.c. with TRAMP-C1 cells and randomised 
into two groups. The first group was treated with the vaccine (107 
IU of ChAdOx1.STEAP1 and 106 PFU of MVA.STEAP1 at 2-week 
intervals) combined with isotype control rat IgG antibody given i.p. 
weekly. The second and third groups received anti-PD-1 or anti-PD-
L1 mAbs weekly in combination with the vaccine. In a different set 
of experiments, challenged mice were only given isotype control rat 
IgG antibody or anti-PD-1 mAb weekly. Tumour size was measured 3 
times per week, and volumes were calculated as described in “Materi-
als and methods”. Data of a representative experiment out of 2 bio-
logical replicates are shown. a Kaplan–Meier survival curves of the 
three groups of mice used in combination therapy experiments. Log-
rank (Mantel–Cox) test P value is shown. b Kaplan–Meier survival 
curves of mice used in Ab only therapy. c Representative graph show-
ing the effect of anti-PD-1 and anti-PD-L1 treatment on the magni-
tude of STEAP1-specific immune responses measured by ex vivo 
blood IFN-γ ELISPOT performed after ChAdOx1 prime–MVA boost 
in the three groups of mice. d Tumour growth curves for each individ-
ual mouse in the three groups, mean tumour volumes ± SEM com-
parison between the three groups and assessment of vaccine efficacy 
by area under the curve (AUC) analysis at day 49 post-TRAMP-C1 
cell inoculation. P values are shown. Bars represent median
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other reports describe the presence of very low levels of 
STEAP1 mRNA in the murine thymus [8, 29, 30]. This 
point remains controversial, but presumably if the thymic 
negative selection of T-cells with STEAP-reactive TCR 
does take place, it is not completely effective, as sponta-
neous STEAP-specific CD8+ T-cell responses have been 
detected in peripheral blood of PCa patients and in vitro re-
stimulation has been described [31]. It appears that even if 
low levels of STEAP1 mRNA are present in the thymus, 
during the process of negative selection STEAP1-specific 
immature T-cells do not encounter their cognate antigen 
sufficiently to purge them from the T-cell repertoire and are 
allowed into secondary lymphoid organs and the periphery. 
The screening for thymic expression may be a promising 
approach for initial selection of potential target antigens for 
vaccine development.
In this article, we have shown that STEAP1 ChAdOx1–
MVA vaccination platform delays growth of pre-estab-
lished ectopic tumours at the early stages of tumour growth 
and modestly controls autochthonous tumours in TRAMP 
mice. Our data are in line with results published by others, 
where diverse prime/boost immunisation regimes targeting 
STEAP failed to significantly delay growth of established 




































































Fig. 5  STEAP1 vaccination reduces tumour burden and increases 
T-cell infiltration in the prostate in spontaneous prostate cancer 
model. A 3-week interval vaccination was initiated on 6- to 8-week-
old TRAMP mice using 108 IU of ChAdOx1.STEAP1 and 107 PFU 
of MVA.STEAP1. Immunised and control unvaccinated TRAMP 
mice were sacrificed at 25–27 weeks of age, and genitourinary tracts 
(GUTs) were dissected, weighed and embedded in paraffin. Rep-
resentative data of 3 biological replicate experiments are shown. a 
Ratio of GUT wet weight to whole body weight in control and immu-
nised TRAMP mice at 25–27 weeks of age. Bars represent median. 
b, c Immunohistochemistry staining of GUTs in STEAP1 vaccinated 
and control mice. Quantitative analysis and representative pictures of 
Ki-67 positive staining (b) and CD3 expression (c) of FFPE prostate 
tissue sections. Bars represent median. Brown regions indicate immu-
noreactivity; counterstain is haematoxylin (×200). Scale bar 100 μm
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Overall, our results show that ectopic tumour growth can 
be delayed and disease progression can be inhibited in mice 
by STEAP1-specific T-cell responses, although tumour 
development could not be completely prevented despite the 
strong immunogenicity of the vaccine. There are a number 
of factors that could potentially contribute to the relatively 
inefficient control of neoplastic growth by vaccines. These 
include, but are not limited to, a natural immunosuppressive 
tumour microenvironment [32], active adaptive immune 
resistance [33, 34], impaired trafficking of immune cell 
into the tumour core [35] and impaired antigen processing 
and presentation by tumour cells [36]. We have investigated 
the potential impact of some of these factors on STEAP1 
vaccine efficacy. TRAMP-C1 cells have been previously 
reported to express low levels of MHCI molecules [20, 
37], and we demonstrate that upon IFN-γ treatment, MHCI 
surface expression dramatically increases in this cell line. 
Another important consideration is that natural expression 
of STEAP1 in TRAMP-C1 cells is low, and the number 
of the MHC–peptide complexes on the cell surface is not 
sufficient to activate STEAP1-specific responses in vitro. 
Similarly to other published data [27], here we show that 
TRAMP-C1 cells are able to efficiently stimulate IFN-γ 
secretion only when exogenously loaded with STEAP1 pep-
tides. Thus, it is likely that TRAMP tumours are not recog-
nised by vaccination-induced low-avidity T-cells because of 
their low MHCI and STEAP1 endogenous expressions. The 
low functional avidity of STEAP1-specific T-cells combined 
with the low level of MHCI–peptide complexes on target 
cells probably contributes to vaccine inefficiency. Indirect 
evidence supporting this hypothesis come from other PCa 
vaccine studies in TRAMP mice, where instead of relying 
on the natural expression of prostate-associated antigens in 
TRAMP tumours, investigators have chosen to use HA or 
SV40 T antigen as model tumour self-antigens [38, 39].
To improve vaccine efficacy, we explored the impact 
of reduced dose and shorter intervals of immunisations 
on tumour progression. We hypothesised that exposure 
to a lower amount of antigen could favour activation of 
high-avidity STEAP1-specific T-cells, which would be 
more efficient in targeting weakly immunogenic TRAMP-
derived tumours. Generally, low-dose vaccination is known 
to stimulate low-frequency high-avidity T-cell responses, 
whereas high-dose peptide stimulates a larger frequency 
but low-avidity responses [40]. Importantly, our results 
show that a tenfold reduction in the vaccine dose has no 
impact on the magnitude of T-cell responses.
The rationale for decreasing intervals between ChAdOx 
and MVA vaccinations was based on several considera-
tions. Firstly, long intervals between immunisations proved 
to be the most efficacious in mouse malaria challenge stud-
ies [41] might not be optimal in murine cancer models. 
Assuming that, following immunisations against a weakly 
immunogenic self-antigen, the pool of activated T-cells is 
smaller and cell activation status is lower, shorter intervals 
between immunisations may be beneficial. Secondly, the 
rapid tolerisation of activated T-cells in circulation when 
they reach tumour sites [38, 42] and the aggressiveness of 
the TRAMP tumour model suggest that frequent fresh sup-
ply of effector cells could result in a better tumour growth 
control. In fact, several publications demonstrated that 
good tumour-protective efficacy was achieved with one-
week interval immunisations [39, 43]. To conclude, our 
experimental data confirmed that a reduced vaccine dose 
and shorter intervals between boosts elicit strong and sus-
tained IFN-γ responses and increase vaccine efficacy.
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Fig. 6  TRAMP-C1 cells are not able to efficiently present STEAP1 
to T-cells. a Analysis of MHCI surface expression in TRAMP-C1 
cells by flow cytometry. TRAMP-C1 cells or TRAMP-C1 cells pre-
treated with IFN-γ were gently dissociated and stained with HB-51 
hybridoma supernatant containing monoclonal anti MHCI antibodies 
(black), or with control medium (grey). Flow cytometry staining is 
shown as normalised histograms. b Western blot analysis of STEAP 
expression in LNCaP (lane 2), PC3 (lane 3), TRAMP-C1 (lane 4), 
HEK293A (lane 5), ChAdOx1.GFP infected HEK293A (lane 6), and 
ChAdOx1.STEAP1 infected HEK293A (lane 7) cells. Lane 1 repre-
sents molecular weight markers. Arrow indicates STEAP1 bands. c 
Splenocytes were incubated with serial dilutions of STEAP1 pools, 
TRAMP-C1 cells or TRAMP-C1 cells preloaded with STEAP1 
pools, and T-cell avidity measured by IFN-γ ELISPOT assay. Bars 
represent SD
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Currently, the tumour adaptive immune resistance and 
checkpoint blockade are under intense investigation [33, 
34, 44], and anti-tumour activity of vaccines was found 
increased when combined with antibodies blocking PD-1 
or PD-L1 [45–47].
The clinical activity of checkpoint monotherapy has 
been confirmed in melanoma, renal and lung cancer. This 
approach may be also advantageous for targeting PCa. In 
this study, we have tested whether it is possible to optimise 
our strongly immunogenic but moderately efficacious vac-
cination platform intervening on the PD-1/PD-L1 axis. Our 
results show that blockade of PD-1 enhances the efficacy 
of STEAP1 vaccination in the subcutaneous tumour model 
significantly improving survival of STEAP1-vaccinated 
mice compared to STEAP1 vaccine or anti-PD-1 therapy 
alone. Interestingly, in a recent study Rekoske et al. [47] 
found that immunisation of tumour-bearing mice with a 
modified, more immunogenic DNA vaccine elicited a sur-
prisingly limited anti-tumour effect relative to the native 
vaccine. They demonstrated that antigen-specific CD8+ 
T-cells from mice immunised with the optimised con-
struct expressed higher PD-1 and, partly in line with our 
observations, anti-tumour activity of the optimised vaccine 
increased when combined with PD-1 or PD-L1 blocking 
antibodies. Of note, we could not detect any effect of anti-
PD-1 mAb treatment on the magnitude of STEAP1-specific 
T-cell responses in circulation, suggesting that the observed 
synergistic effect could be taking place at the tumour site 
[48, 49]. We should also mention that in our hands, no 
beneficial effect was obtained using anti-PD-L1 antibody 
therapy in a combinatorial approach, possibly reflecting the 
fact that PD-L1 is not upregulated in this tumour model, 
similarly to human PCa [50].
To conclude, data presented in this study demonstrate 
that ChAdOx1–MVA-based vaccination strategy targeting 
prostate-associated antigen STEAP1 is able to elicit strong 
sustained STEAP1-specific immunity in mice and confers 
partial tumour protection in transplantable and spontane-
ous PCa mouse models. Also, our vaccination regime in 
combination with PD-1 therapy significantly improves sur-
vival in tumour-bearing animals. We believe that STEAP1 
ChAdOx1–MVA vaccination has high therapeutic poten-
tial and an improved efficacy in pre-clinical animal models 
could rapidly translate into clinical use.
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